CLIN Clinigen Group Plc

TIDMCLIN

RNS Number : 7128V

Clinigen Group plc

07 November 2017

7 November 2017

Grant of Share Options

Clinigen Group plc (AIM: CLIN, "Clinigen" or the "Company"), announces that, on 6 November 2017, the following Directors were granted share options over a total of 122,995 ordinary shares of 0.1 pence each ("Ordinary Shares"), granted under the Clinigen Group Long Term Incentive Plan 2015. The options are nil cost options intended to vest on 16 October 2020 subject to the achievement of certain performance criteria.

The additional share options granted to Shaun Chilton are in relation to the completion of the acquisition of Quantum Pharma plc.

 
 Director/PDMR       Number   Total number   Total number      Total number 
                   of share       of share    of ordinary       of ordinary 
                    options        options         shares            shares 
                    granted       now held       now held        (excluding 
                                                             share options) 
                                                                as % issued 
                                                              share capital 
---------------  ----------  -------------  -------------  ---------------- 
 Shaun Chilton       43,630        318,420        312,943             0.26% 
---------------  ----------  -------------  -------------  ---------------- 
 Chris Rigg          79,365         79,365          6,563             0.01% 
---------------  ----------  -------------  -------------  ---------------- 
 

-Ends-

Contact details

 
 Clinigen Group plc                  Tel: +44 (0) 1283 
                                      495010 
 Shaun Chilton, Group Chief 
  Executive Officer 
 Martin Abell, Group Chief 
  Financial Officer 
 
 Numis Securities Limited            Tel: +44 (0) 20 
                                      7260 1000 
 Michael Meade / Freddie Barnfield 
  (Nominated Adviser) 
  James Black / Tom Ballard 
  (Corporate Broking) 
 
 RBC Capital Markets - Joint         Tel: +44 (0) 20 
  Broker                              7653 4000 
  Marcus Jackson / Elliot Thomas 
   / Jack Wood 
 
 Instinctif Partners                 Tel: +44 (0) 20 
                                      7457 2020 
 Melanie Toyne-Sewell / Alex 
  Shaw / Deborah Bell                Email: clinigen@instinctif.com 
 

About Clinigen Group

Clinigen Group plc (AIM: CLIN) is a global pharmaceutical and services company with a unique combination of businesses focused on providing access to medicines. Its mission is to deliver the right medicine to the right patient at the right time through three areas of global medicine supply; clinical trial, unlicensed and licensed medicines.

For more information, please visit www.clinigengroup.com

This information is provided by RNS

The company news service from the London Stock Exchange

END

DSHBFBRTMBBMBIR

(END) Dow Jones Newswires

November 07, 2017 05:00 ET (10:00 GMT)

Clinigen (LSE:CLIN)
Historical Stock Chart
From Apr 2024 to May 2024

Clinigen (LSE:CLIN)
Historical Stock Chart
From May 2023 to May 2024